Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Cardiovascular Therapeutics|July 17, 2009
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonistSteen Husted, J J J van Giezen
Seminars in Thrombosis and Hemostasis|April 27, 2005
Preclinical and clinical studies with selective reversible direct P2Y12 antagonistsJ J J van Giezen, Robert G Humphries
Platelets|November 26, 2005
Evaluation of platelet function, a method comparisonS Nylander, K Johansson, J J J Van Giezen, et al.
Thrombosis Research|August 23, 2012
Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine modelAnna Ravnefjord, Jessika Weilitz, Britt-Marie Emanuelsson, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|June 24, 2011
Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine modelJ J J van Giezen, James Sidaway, Philip Glaves, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|January 14, 2014
Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1Duncan Armstrong, Claire Summers, Lorna Ewart, et al.
Journal of the American College of Cardiology|January 15, 2013
Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humansAnn Wittfeldt, Håkan Emanuelsson, Gunnar Brandrup-Wognsen, et al.
Journal of Thrombosis and Haemostasis : JTH|June 26, 2009
Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregationJ J J VAN Giezen, L Nilsson, P Berntsson, et al.
Pageof 2